NEW YORK (GenomeWeb) –Bristol-Myers Squibb plans to use Natera's circulating tumor DNA assay, Signatera, to determine whether it can successfully identify non-small cell cancer patients who might benefit from BMS's Opdivo (nivolumab) immunotherapy, Natera announced today.

Patients enrolled in the study will first undergo surgical resection of their tumor. The Signatera assay will be used to select patients with minimal residual disease to receive standard of care adjuvant therapy or adjuvant therapy plus Opdivo.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
04

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Oct
10

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.